

Supply Shortage of ORENCIA® (abatacept) 125 mg solution for injection in pre-filled pen (ClickJect)

June 2024

Dear Customer,

Bristol-Myers Squibb (BMS) Pharma EEIG regrets to inform you that we are facing a temporary supply shortage of *ORENCIA® (abatacept) 125 mg solution for injection in pre-filled pen (ClickJect - PLGB 15105/0174)* to the Great Britain market.

Summary:

- A temporary supply shortage of the *ORENCIA® (abatacept) 125 mg pre-filled pen (ClickJect)* is currently anticipated to commence from mid-June 2024 in Great Britain due to a manufacturing issue resulting in delays in production.
- Supply of the ClickJect presentation is anticipated to return to normal levels by September 2024, but this is subject to change. Updated information on return to supply will be communicated to the Department of Health & Social Care (DHSC).
- Homecare providers (Lloyds Pharmacy Clinical Homecare (LPCH), HealthNet and Polar Speed) have sufficient stock of the ClickJect presentation to supply existing patients until the week ending 23 June 2024.
- The constrained supply situation does not apply to the availability of the *ORENCIA® (abatacept) 125 mg solution for injection in pre-filled syringe (PLGB 15105/0134)* or *250 mg powder for concentrate for solution for infusion (PLGB 15105/0135)* presentations for existing patients. There is potential for a limited number of patients to switch from the ClickJect presentation to the pre-filled syringe.
- Sufficient stock of the 250 mg powder for concentrate for solution for infusion (IV presentation) exists to meet an increase in demand during this period. Although the IV presentation is an available alternative for eligible patients, the switch from Clickject is complex and requires management and supervision by an appropriate clinician. LPCH and Polar Speed can support the administration of the IV presentation during this period.
- To help us manage stocks of the ClickJect presentation in the coming months we would ask that new patients are not started on abatacept treatment. Please prioritise ordering/prescribing the ClickJect presentation for patients with the greatest needs or when alternative treatments are not suitable.

- BMS is working diligently to resolve the supply shortage as soon as possible. We regret any inconvenience caused by this temporary supply interruption to the market.
- Please see the [DHSC and NHS National Patient Safety Alert](#) for further information on this shortage.
- For further details on the product, please refer to the approved product information available at: [medicines.org.uk/emc/orencia](https://www.medicines.org.uk/emc/orencia)

Please ensure all relevant personnel are made aware of the content of this letter and that the information is communicated to patients.

Reporting of suspected adverse reactions

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Bristol Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

Company Contact Point

If you have any medical questions in relation to this communication, please contact the BMS Medical Information department at 0800 731 1736 or via email at medical.information@bms.com

Yours sincerely,

Dr Hosnieh Fathi

[Dr Hosnieh Fathi \(Jun 6, 2024 12:36 GMT+1\)](#)

Dr Hosnieh Fathi - MD, EMBA, FFPM
Director, UK/IE Disease Area Head for Innovative Medicines
Bristol Myers Squibb

Job Code: 427-GB-2400008
Date of Preparation: June 2024